Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 5/20 | 0.54 |
| ▸ | MAOB | P27338 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
| ▸ | STING1 | Q86WV6 | 3/20 | 0.51 |
| ▸ | CA1 | P00915 | 1/20 | 0.50 |
| ▸ | CA2 | P00918 | 1/20 | 0.50 |
| ▸ | PARP1 | P09874 | 1/20 | 0.50 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.50 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.49 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27213711 | 0.87 | RAB9A (0.64) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL27213893 | 0.86 | LMNA (0.55) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL29322211 | 0.83 | HTT (0.47) | PARP10MAOBNPC1POLBRAB9A | |
| SCHEMBL14699807 | 0.80 | RAB9A (0.58) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL14882567 | 0.80 | MAOB (0.51) | MAOBNPC1POLBRAB9ASMN1; SMN2 | |
| SCHEMBL12339549 | 0.79 | PARP10 (0.83) | PARP10MAOBNPC1POLBRAB9A | |
| SCHEMBL14699815 | 0.79 | MAPT (0.50) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL3354489 | 0.79 | SMN1; SMN2 (0.57) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL2312758 | 0.78 | LMNA (0.49) | NPC1POLBRAB9ASMN1; SMN2ALDH1A1 | |
| SCHEMBL18397061 | 0.78 | KDM4E (0.59) | PARP10NPC1RAB9ASMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4598908-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | Pfizer Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | PFIZER INC. (US) | 2024-07-18 | — | — | US | disclosed |
| WO-2024075051-A1 | HSD17B13 INHIBITORS AND/OR DEGRADERS | PFIZER INC. (US) | 2024-04-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240238425-A1 | HSD17B13 Inhibitors and/or Degraders | HSD17B13, HSD17B3, HSD17B1 | PARP10 1883/4885MAOB 133/4885NPC1 999/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.